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Abstract
Background: Boswellic acids mixture of triterpenic acids obtained from the oleo gum resin of Boswellia serrata and
known for its effectiveness in the treatment of chronic inflammatory disease including peritumor edema. Boswellic
acids have been extensively studied for a number of activities including anti inflammatory, antitumor,
immunomodulatory, and inflammatory bowel diseases. The present study describes the antimicrobial activities of
boswellic acid molecules against oral cavity pathogens. Acetyl-11-keto-b-boswellic acid (AKBA), which exhibited the
most potent antibacterial activity, was further evaluated in time kill studies, mutation prevention frequency,
postantibiotic effect (PAE) and biofilm susceptibility assay against oral cavity pathogens.
Findings: AKBA exhibited an inhibitory effect on all the oral cavity pathogens tested (MIC of 2-4 μg/ml). It
exhibited concentration dependent killing of Streptococcus mutans ATCC 25175 up to 8 × MIC and also prevented
the emergence of mutants of S.mutans ATCC 25175 at 8× MIC. AKBA demonstrated postantibiotic effect (PAE) of
5.7 ± 0.1 h at 2 × MIC. Furthermore, AKBA inhibited the formation of biofilms generated by S.mutans and
Actinomyces viscosus and also reduced the preformed biofilms by these bacteria.
Conclusions: AKBA can be useful compound for the development of antibacterial agent against oral pathogens
and it has great potential for use in mouthwash for preventing and treating oral infections.
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Background
Several microorganisms inhabit the human oral cavity,
and there is always a risk of infection with bacterial
pathogens associated with the oral cavity. Streptococcus
constitutes 60 to 90% of the remaining bacteria that colo-
nize the teeth within the first 4 h after professional clean-
ing [1]. Other early colonizers include Actinomyces spp.,
Eikenella spp., Haemophilus spp., Prevotella spp., Propio-
nibacterium spp., and Veillonella spp. Many of the physi-
cal interactions that occur between the organisms of this
community are known. Streptococcus is the only genus of
oral cavity bacteria that demonstrates extensive and inter-
genic coaggregation [2,3]. The ability of this genus to
bind to other early colonizers and to host oral matrices
may confer an opportunity to viridians streptococci in
establishing early dental plaque [1]. Streptococcus mutans
can colonize the tooth surface and initiate plaque
formation by its ability to synthesize extracellular polysac-
charides, mainly water-insoluble glucan from sucrose,
using its glucosyltransferase [4]. It is a key contributor to
the formation of biofilms associated with dental caries
disease. The biofilms of S. mutans are also involved in
infective endocarditis, a serious disease with a mortality
rate of up to 50% despite antibiotic treatment [5]. The
current research targeting microbial biofilm inhibition
has attracted a great deal of attention, and the search for
effective antimicrobial agents against these oral pathogens
could lead to identification of new agents for the preven-
tion of dental caries and periodontal diseases arising out
of dental plaque formation [6]. A variety of plant materi-
als and phytochemicals, especially a class of essential oils,
have long been found to exhibit effective antibacterial
activity [7]. The aromatic molecules derived from natural
sources are being explored extensively as alternative
agents in oral care products. There is some evidence that
many natural molecules are good antibacterial agents that
show activity against oral pathogens like Fusobacterium
nucleatum, Actinomyces viscosus, S. mutans, Prevotella
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intermedia, Haemophilus actinomycetemcomitans, Strep-
tococcus sanguis and Prophyromonas gingivalis [8-11].
Boswellic acids, major constituents of the gum resin
derived from the plant Boswellia serrata, comprises of b-
boswellic acids as the main triterpenic acid along with 11-
keto-b-boswellic acids and their acetates [12]. The gum
exudate is known for its anti-inflammatory properties in
the Ayurvedic system of medicines [13,14]. The alcoholic
extract of the gum is used for the treatment of adjuvant
arthritis [15]. It has synergistic effect with glucosamine, an
anti-inflammatory and anti-arthritic agent [16]. Acetyl-11-
keto-b-boswellic acid (AKBA), a component of the gum
exudate is a pentacyclic terpenoid and is reported to be
active against a large number of inflammatory diseases
[17,18] including cancer, arthritis, chronic colitis, ulcera-
tive colitis, Crohn’s disease, and bronchial asthma [19-21].
In addition to these therapeutic effects, our recent studies
have revealed antibacterial properties of AKBA against
various clinical isolates and ATCC strains of Gram posi-
tive bacteria [22]. The aim of study was to evaluate the
antibacterial activity of acetyl-11-keto-b-boswellic acid
against a panel of oral cavity pathogens and its biofilm
inhibitory potential for Streptococcus mutans ATCC
25175 (cariogenic bacteria) and Actinomyces viscocsus
ATCC 15987 (noncariogenic bacteria).
Methods
Extraction and isolation of boswellic acid molecules from
gum resin of Boswellia serrata
b-boswellic acid (BA), 11-keto-b-boswellic acid (KBA),
Acetyl-b-boswellic acid (ABA) and acetyl-11-keto-b-bos-
wellic acid (AKBA) were obtained from Bioorganic
Chemistry Division of Indian Institute of Integrative
Medicine Jammu, India. The extraction, isolation, and
quantification of these compounds from gum resin of
Boswellia serrata were described in our previous study
[16,23].
Bacterial strains and culture conditions
The pathogenic bacterial strains were obtained from
ATCC (American Type Culture Collection, Manassas,
VA, USA). Streptococcus mutans ATCC 25175, Entero-
coccus faecalis ATCC 29212, Enterococcus faecium
ATCC 8042 were maintained by sub culturing on Tryti-
case Soy agar (TSA; DIFCO Laboratories, Detroit, MI,
USA) at 37°C. Cultures of Actinomyces viscosus ATCC
15987 and Streptococcus sanguis ATCC 10556 were
maintained on Brain heart infusion agar (BHI; DIFCO
Laboratories) at 37°C in a 5% CO2 atmosphere. Porphyr-
omonas gingivalis ATCC 33277, Fusobacterium nuclea-
tum ATCC 10953, and Prevotella intermedia ATCC
25611 were maintained on Wilkins Chalgren agar
(WCA; DIFCO Laboratories) in an anaerobic gas jar at
37°C.
Minimum inhibitory concentrations (MIC) and minimum
bactericidal concentrations (MBC) of boswellic acids
against oral cavity pathogens
MIC was determined as per the guidelines of Clinical and
Laboratory Standards Institute (formerly the National
Committee for Clinical Laboratory Standards) [24]. All
oral cavity bacteria used in this study were grown to
stationary phase for 24 h at 37°C. Bacterial suspensions
were prepared by suspending 24 h grown culture in
Brucella broth (BB; DIFCO Laboratories) (for anaerobic
bacteria) and sterile normal saline (0.89% NaCl wt/vol;
Himedia, Mumbai India, for aerobic bacteria). The
turbidity of bacterial suspension was adjusted to 0.5
McFarland standard, which is equivalent to 1.5 × 108
CFU/ml. The boswellic acids stock solutions were pre-
pared in 100% dimethyl sulfoxide (DMSO; Merck, Mum-
bai India) and 2-fold serial dilutions were prepared in
Mueller Hinton Broth (MHB; Difco Laboratories) for aero-
bic bacteria, Brain heart infusion broth (BHI) for 5% CO2
cultures and WCB for anaerobic bacteria) respectively in
100 μl volume in 96-well U bottom microtiter plates (Tar-
son, Mumbai, India). The above-mentioned bacterial sus-
pension was further diluted in respective growth media
and 100 μl volume of this diluted inoculum was added to
each well of the plate resulting in the final inoculum of
5 × 105 CFU/ml in the well and the final concentration of
boswellic acids ranged from 0.25 to 128 μg/ml. Triclosan
was used as standard antibacterial agent for this study at a
concentration ranged from 0.03-16 μg/ml. The plates were
incubated at 37°C for 24 h and were visually read for the
absence or presence of turbidity. The minimum concen-
tration of the compound concentration showing no tur-
bidity was recorded as MIC. The MBC was determined by
spreading 100 μl volume on tryptic soy agar (TSA) plate
from the wells showing no visible growth. The plates were
incubated at 37°C for overnight.
Time kill studies against S. mutans
S. mutans ATCC 25175 was grown in BHI broth at 37°C
for 24 h. The turbidity of the suspension was adjusted to
0.5 McFarland (≈ 1.5 × 108 CFU/ml) in sterile normal
saline. Two hundred microliters of this suspension was
used to inoculate 20 ml of BHI broth conical flask con-
taining AKBA in the concentration range of 8-32 μg/ml.
DMSO controls were also included in the study. The
flasks were incubated at 37°C. One hundred microliters
samples were taken at 0, 1, 2, 4, 6, 8, 10, and 24 h and the
viable counts were determined in triplicate on TSA. Kill-
ing curves were constructed by plotting the log10 CFU/
ml versus time over 24 h [25].
Selection of resistant mutants in vitro
The first-step mutants of S. mutans ATCC 25175 were
selected using a previously described method [26].
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A bacterial suspension containing 109 CFU (100 μl) was
plated on BHI agar containing AKBA at concentrations
equal to 2×, 4×, and 8× MIC. Mutation frequency was
calculated by counting the total number of colonies
appearing after 48 h of incubation at 37°C in 5% CO2
on the AKBA-containing plate and by dividing the num-
ber by the total number of CFU plated. All mutation
prevention concentration determinations were made in
triplicate, and the results were identical.
Postantibiotic effect (PAE)
The PAEs of the AKBA were assessed by the method
described by Craig and Gudmundsson [27]. AKBA was
added at the MIC and 2 × MIC to test tubes containing
≈106 CFU/ml of S. mutans ATCC 25175 in BHI broth.
After an exposure of 2 h to the AKBA, samples were
diluted to 1:1,000 in same medium to effectively remove
AKBA. CFU was determined from the sample every hour
until visual cloudiness was noted. The PAE was calcu-
lated by the equation: PAE = T - C, where T represents
the time required for the count in the test culture to
increase 1 log10 CFU/ml above the count observed imme-
diately after drug removal and C represents the time
required for the count of the untreated control tube to
increase by 1 log10 CFU/ml.
Biofilm susceptibility assays
The biofilms of S. mutans ATCC 25175 and A. viscosus
ATCC 15987 were prepared in 96-well flat-bottom poly-
styrene microtiter plates (Tarson, Mumbai, India), using a
previously described method of Wei et al. [28] with a few
modifications. This method was similar to the MIC assay
for planktonic cells. The bacterial suspensions were pre-
pared from the overnight grown culture and the turbidity
of the suspension was adjusted to 0.7 O.D.610 (≈1 × 109
CFU/ml). Twofold serial dilutions of boswellic acids were
prepared in 100 μl volume in BHI supplemented with 2%
sucrose in the wells of 96-well flat bottom microtiter plate.
Forty microliters of fresh BHI with 2% sucrose was added
to each well, followed by the addition of 60 μl of above
bacterial suspension. This resulted in the final inoculum of
6 × 107 CFU/ml in each well: the final concentrations of
the compounds ranged from (0.12 to 128 μg/ml). The
plate was incubated for 18 h at 37°C in 5% CO2 for 24 h,
absorbance at 595 nm was recorded to assess the culture
growth. After completion of incubation, the planktonic
cells were removed from each well by washing with phos-
phate buffer saline (Himedia, Mumbai, India). The bio-
films were fixed with methanol for 15-30 min, stained
with 0.1% (wt/vol) Crystal Violet (Sigma Chemical Co., St
Louis, MO, USA). The biofilm was rinsed thoroughly with
water until the control wells appeared colourless. Biofilm
formation was quantified by the estimation of biofilm
mass (glucans matrix containing bacterial cells) with the
addition of 200 μl of 95% ethanol to each Crystal Violet-
stained well. The plate was put on a shaker at room tem-
perature for 30 min and the absorbance at 595 nm (A595)
was determined using a microplate reader (Multiskan
Spectrum; Thermo Electron, Vantaa, Finland). The per-
centage of inhibition was calculated using the equation
(1-A595 of the test/A595 of nontreated control) ×100.
Culture without the agents was used as the no-treatment
control. The minimum biofilm inhibition concentration
(MBIC50) was defined as the lowest agent concentration
that showed 50% or more inhibition on the formation of
biofilm.
The effect of AKBA was also examined on preformed
biofilm. The biofilms were prepared by inoculating the
suspension of S. mutans ATCC 25175 and A. viscosus
ATCC 15987 into the wells of a polystyrene microtiter
plate as mentioned above. After incubation at 37°C in 5%
CO2 for 24 h, the culture supernatant from each well was
decanted, and the planktonic cells were removed by wash-
ing the wells with PBS (pH 7.2). Twofold serial dilutions
of AKBA were prepared in BHI broth, and 200 μl of each
dilution was added to the biofilm in the wells. The plate
was further incubated at 37°C in 5% CO2 for 24 h. The
biofilm was fixed, stained, and quantified as described
above.
Statistical analysis
All experiments were carried out in triplicates in at least
three different occasions. Differences between two means
were evaluated by the Student’s t-test. The data were ana-
lyzed by one-way ANOVA for comparison of multiple
means followed by Bonferroni test using GraphPad Instat2
program (GraphPad software Inc. San Diego CA). The
chosen level of significance for all statistical tests was P <
0.05.
Results
MIC and MBC of boswellic acids
The in vitro antibacterial activities of boswellic acids were
tested on a group of clinically significant panel of oral
bacteria (Table 1). AKBA was the most active of the four
boswellic acids against all bacterial pathogens. AKBA
exhibited MIC ranging from 2-4 μg/ml against all the
tested strains except against F. nucleatum ATCC 10953
showing MIC > 128 μg/ml, whereas KBA and BA exhib-
ited moderate Gram-positive antibacterial activity (MIC
≈ 8-64 μg/ml). ABA on the other hand was completely
devoid of antibacterial activity up to the tested concen-
tration of 128 μg/ml. All the compounds were bacterio-
static in nature and exhibited an MBC > 128 μg/ml.
Since AKBA was found to be the most active boswellic
acid compound against Gram-positive bacterial patho-
gens, further in vitro studies were performed on this
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compound against clinically important S. mutans and
A. viscosus.
Time-kill kinetic studies
The time-kill kinetics studies were specifically per-
formed against S. mutans ATCC 25175 owing to its
importance in the initiation of plaque formation (Figure
1). It showed bacteriostatic activity at all the tested con-
centrations. The maximum effect of AKBA was
observed at 16 and 32 μg/ml exhibiting a ≈2 log10
reduction in the viability of S. mutans cells when com-
pared with non treated controls (P < 0.05) at four and
eight times it’s MIC over a period of 24 h study.
Frequency of emergence of AKBA resistance
The frequencies of mutant selection of S. mutans ATCC
25175 are shown in table 2. AKBA at 16 μg/ml (8 × MIC)
completely suppressed the emergence of mutants. This
concentration of AKBA at which no mutant was selected
can be defined as the mutation prevention concentration.
Table 1 Antibacterial activity of boswellic acid molecules against Oral pathogens
Organisms KBA AKBA BA ABA
Triclosan MICa MICa MICa MICa MBCb
S. mutans ATCC 25175 4 16 2 32 > 128 > 128
E. faecalis ATCC 29212 4 16 4 8 > 128 > 128
E. faecium ATCC 8042 4 16 4 8 > 128 > 128
A. viscosus ATCC 15987 4 8 2 64 > 128 > 128
S. sanguinis ATCC 10556 4 8 2 128 > 128 > 128
F. nucleatum ATCC 10953 2 > 128 > 128 > 128 > 128 > 128
P. intermedia ATCC 25611 1 16 4 32 > 128 > 128
P. gingivalis ATCC 33277 2 8 4 32 > 128 > 128
MICs and MBCs of boswellic acid molecules were determined using CLSI guidelines against ATCC strains. aMinimum Inhibitory Concentration (μg/ml); bMinimum
Bactericidal Concentration (μg/ml);
 
Figure 1 Effect of AKBA at different concentrations (8, 16 and 32 μg/ml) on the cell viabilty of S.mutans ATCC 25175. S. mutans cells
without AKBA served as control. The effect of AKBA was observed bacteriostatic at all tested concentrations when compared with non treated
control (P < 0.05) over a period of 24 h study. Each time point represents the mean log10 standard deviations (± SD) of three different
experiments performed in duplicate. *, P <0.05; (Student’s t test).
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Postantibiotic Effect (PAEs)
The PAE of AKBA was determined on S. mutans (Table 3).
The PAE induced by AKBA was concentration dependent,
with duration 3.5 ± 0.1 h at 1 × MIC while at 2 × MIC it
was 5.7 ± 0.1 h. Ciprofloxacin was used as control drug in
the study and it exhibited a PAE of 1.4 ± 0.05 h at 1 ×
MIC while at 2 × MIC it was 2.2 ± 0.1 h (0.5 μg/ml). The
PAEs of AKBA were significantly higher than the ciproflox-
acin against S. mutans (P < 0.05).
Biofilm inhibition and reduction
AKBA effectively inhibited the formation of S. mutans and
A. viscosus biofilms, with 50% biofilm inhibition concen-
tration (MBIC50) 16 μg/ml (as derived from Figure 2A)
which is in the range of 8 × MIC. AKBA also effectively
eradicated the preformed biofilms. The 50% biofilm reduc-
tion concentration (MBRC50) ranged 32 μg/ml for both
the bacterial isolates (Figure 2B).
Discussion and conclusions
Boswellic acid obtained from the bark of Boswellia serrata
was studied for its inhibitory activity against oral cavity
pathogens. The in vitro antibacterial activity results of four
boswellic acid compounds revealed AKBA to be the most
potent antibacterial compound against all the bacteria
tested including S. mutans, E. faecium, E. faecalis, S. san-
guis, A. viscosus, P. intermedia and P. gingivalis. AKBA
exerted bacteriostatic antibacterial activity against S.
mutans (Figure 1) and exhibited a good PAE of 5.7 h at
2 × MIC concentration. AKBA at 8 × MIC also prevented
the emergence of mutants of S. mutans and A. viscosus.
Bacteria in a biofilm are invariably less susceptible to
antimicrobial agents than their planktonic counterparts
[29]. Biofilm infections are difficult to treat due to their
inherent antibiotic resistance [30-32]. Oral biofilms are
associated with the most common infections in the oral
cavity such as caries, gingivitis and periodontal diseases
[31]. Oral microbial-plaque communities are biofilms
composed of numerous genetically distinct types of bac-
teria that live in close juxtaposition on host surfaces.
These bacteria communicate through physical interactions
called coaggregation and coadhesion, as well as other phy-
siological and metabolic interactions [2,3]. The early colo-
nizers namely Streptococcus mutans and Actinomyces
viscosus (mainly from Gram-positive bacteria) initiate the
process of acid formation, its deposition and subsequent
action on the enamel of the teeth which sets in the process
of decalcification and development of dental caries
[1,33,34]. AKBA effectively inhibited the S. mutans (cario-
genic bacteria) and A. viscosus (noncariogenic bacteria)
biofilms and also reduced the preformed biofilm of these
bacterial pathogens (P < 0.05). To our knowledge, this is
the first report to provide the evidence that AKBA can
prevent as well as reduce the S. mutans and A. viscosus
generated biofilms.
In our previous study, we have reported the first time
AKBA as the single most potent antibacterial compound
present in the gum exudates of Boswellia serrata [22], and
in this study, first we are reporting AKBA as an antibacter-
ial and antibiofilm agent against oral cavity pathogens.
AKBA is reported to be active against a large number of
inflammatory diseases, cancer, arthritis, chronic colitis,
ulcerative colitis, Crohn’s disease, and bronchial asthma
[19,20,35-37]. The anticancer activity of AKBA is attribu-
ted to the inhibitory effect on the lipoxygenases leading to
the inhibition of cell proliferation and induction of apop-
tosis in tumor cells [38]. There are numerous reports
available on the antibacterial activity of oleo-gum resin
extracts and oleo-gum resin essential oils from Boswellia
spp. (Burseraceae) [39-41]. Weckessera et al. [42] reported
the antibacterial activity of Boswellia dry extract and keto-
b-boswellic acid. Their findings revealed that the extract
was highly effective against selected aerobic and anaerobic
bacteria such as Streptococcus, Corynebacteria, C. perfrin-
gens and P. acnes; whereas KBA was not effective against
these pathogens, suggesting that the effective components
are other boswellic acids or essential oils contained in the
extract.
Gum resin of boswellia is included in the list of sub-
stances Generally Recognized As Safe (GRAS), thereby
permitting its use as food additive by US FDA. Boswellic
acid extract and AKBA have also been reported to be
safe and exert minimal toxicity on human skin cells [43].
Table 2 Frequency of mutation with Acetyl-11-keto-b-
boswellic acid against S.mutans ATCC 25175
Compounds Mutation frequency with AKBA at:a
2 × MIC 4 × MIC 8 × MIC
Acetyl-11-keto-b-boswellic acid 3 × 10-9 3 × 10-9 < 3 ×10-9
Ciprofloxacin 2.5 × 10-6 3.5 × 10-8 1.5 × 10-9
a The MIC of Acetyl-11-keto-b-boswellic acid is 2 μg/ml.
MPC were performed on S. mutans ATCC 25175. The rate of mutation
frequency was calculated by dividing total number of colonies appearing on
the drug containing plate by total number of CFU plated. AKBA at 16 μg/ml
(8 × MIC) completely suppressed the emergence of mutants. This
concentration of AKBA at which no mutant was selected can be defined as
the mutation prevention concentration (MPC).
Table 3 PAEs of Acetyl-11-keto-b-boswellic acid against S.
mutans ATCC 25175
Compounds Mean PAE (h) ± SD on:
1 × MIC 2 × MIC
Acetyl-11-keto-b-boswellic acid 3.5 ± 0.1a 5.7 ± 0.1b
Ciprofloxacin 1.4 ± 0.05a 2.2 ± 0.1b
The PAEs were monitored by viable count of S. mutans after 2 h exposure to
concentrations equal to MIC and 2 × MIC of antimicrobials (AKBA and
ciprofloxacin). Values in the same column followed by the same superscripts
are significantly different from each other (P < 0.05; Student’s t test). PAE, Post
antibiotic effect.
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The recent study indicates that B. serrata is non-muta-
genic in Ames test, and is non-clastogenic in in-vitro
chromosomal aberration study [44]. Oral preparations of
Boswellic serrata extract containing AKBA are sold in the
market as over the counter (OTC) anti-inflammatory
formulations and are considered to be quite safe [45].
The ancient Indian system of medicine (Ayurveda) claims
these preparations to be safe and effective dietary supple-
ment against joint disorders [46,13,14]. Preliminary phar-






Figure 2 Effect of AKBA on the biofilm formation (A) and preformed biofilm (B) by S. mutans ATCC 25175 and A. viscosus ATCC
15987. After incubation, the biofilms were stained with crystal violet and the optical density of stained biofilm was determined with a
multidetection microplate reader at a wavelength of 595 nm (OD595). The results are expressed as average optical density readings for crystal
violet assays compared to untreated control (without AKBA). The biofilm of S. mutans and A. viscosus were significantly inhibited (A) and reduced
(B) when compared with untreated control (P < 0.05). Values are mean (± SD) from four independent determinations. *, P <0.05 (Student’s t
test).
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concentrations of boswellic acids in plasma [47-49]. In
addition to the above reported usage and safety asso-
ciated with AKBA, the potent antibacterial and anti-bio-
film activities reported in this study warrants that the
structure of AKBA can be further exploited to evolve
potential lead compounds in the discovery of oral care
agents.
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